(PharmaNewsWire.Com, September 24, 2021 ) The increasing burden of UTIs, diabetes, and kidney & liver diseases; rising geriatric population and the subsequent increase in age-associated diseases and increasing adoption of POC diagnostic tests are factors supporting the growth of this market. Growth opportunities in emerging economies provide lucrative opportunities for the players operating in the urinalysis market.
The consumables segment accounted for the largest share of urinalysis market, by product segment, in 2020
Based on product, the urinalysis market is segmented into consumables and instruments. In 2020, the consumables segment accounted for the largest share of this market. The frequent purchase of these products due to their recurrent usage drives the market growth of this segment.
Sediment urinalysis segment to register the highest CAGR during the forecast period
Based on the test type, the urinalysis market has been segmented into pregnancy & fertility tests, biochemical urinalysis and sediment urinalysis. In 2020, the sediment urinalysis segment accounted for the highest CAGR. This can be primarily attributed to the increasing adoption of automated devices for sediment analysis.
COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a matter of a few weeks. The COVID-19 pandemic negatively affected the overall sales of most of the companies Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health checkups, thus affecting the number of tests being performed and sales of reagents.
The disease screening segment accounted for the largest share of the urinalysis market, by application segment, in 2020
Based on application, the urinalysis market is segmented into disease screening and pregnancy & fertility. In 2020, the disease screening segment accounted for the largest share of this market. Factors such as the increasing incidence of UTIs, diabetes, liver diseases and kidney ailments worldwide are driving the growth of this market.
The diagnostic laboratories segment accounted for the largest share of urinalysis market, by end user segment, in 2020
Based on end user, the urinalysis market has been segmented into diagnostic laboratories, hospitals and clinics, home care settings and research laboratories & institutes. In 2020, diagnostic laboratories accounted for the largest share of the urinalysis market. Diagnostic laboratories command the major share of the urinalysis market owing to rapidly growing aging population, the increasing global incidence of kidney diseases and UTIs, increase in reimbursements for clinical tests performed in hospitals, and the launch of advanced urinalysis devices such as integrated devices.
Due to rapid growth in the senior population, the prevalence of age-associated diseases such as diabetes, liver, and kidney diseases are expected to increase significantly. The diagnosis and management of such diseases are responsible for the increasing number of prescriptions for tests such as creatinine, albumin, glucose, ketones, and bilirubin, etc. These tests are performed by urinalysis; hence, it is expected to have a positive impact on this market.
In addition to the factors mentioned above, the Asia Pacific has emerged as an adaptive and business-friendly hub due to relatively less stringent regulations and data requirements. Moreover, as markets in the US and Europe are maturing, most players are shifting their focus to emerging markets.
North America is the largest regional market for urinalysis market
The urinalysis market is segmented into five regions, namely, North America, Europe, Asia Pacific, and Rest of the World. In 2020, North America accounted for the largest share of the urinalysis market. The large share of this region can be attributed to growing geriatric population, implementation of favorable government initiatives, increasing healthcare expenditure, improved healthcare infrastructure, and the availability of technologically advanced instruments.
The major players operating in this market are Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Cardinal Health, Inc. (US), Abbott Laboratories (US), Danaher Corporation (US), Sysmex Corporation (Japan), Quidel Corporation (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), EKF Diagnostics (UK), Thermo Fisher Scientific Inc. (US), ARKRAY, Inc. (Japan), ACON Laboratories, Inc. (US), 77 Elektronika Kft. (Hungary), URIT Medical Electronic Group Co., Ltd. (China), Dirui Industrial Co., Ltd. (China), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), BIOBASE Group (China), ERBA Mannheim (UK), Alphatech Scientitfic (Peru), Teco Diagnostics (US), Analyticon Technologies AG (Germany), Bioway Biological Technology Co. Ltd. (China), High Technology Inc. (US) and Agappe Diagnostics Ltd. (India).
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
